drugset / Trial / NCT01394770

Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients

NCT01394770

RandomizedParallel-groupDouble-blindTreatment

Summary

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether aliskiren, a direct renin inhibitor, compared with amlodipine, a calcium channel blocker, reduces mortality and cardiovascular events in these high-risk patients.

Timeline

Start
2009-09
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Amlodipine Other / unclassified 10 mg

Indications